Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Exchange Rate Effect (2017 - 2022)

Historic Exchange Rate Effect for Protagonist Therapeutics (PTGX) over the last 6 years, with Q4 2022 value amounting to $75000.0.

  • Protagonist Therapeutics' Exchange Rate Effect rose 24090.91% to $75000.0 in Q4 2022 from the same period last year, while for Dec 2022 it was -$90000.0, marking a year-over-year increase of 2857.14%. This contributed to the annual value of -$90000.0 for FY2022, which is 2857.14% up from last year.
  • Protagonist Therapeutics' Exchange Rate Effect amounted to $75000.0 in Q4 2022, which was up 24090.91% from -$175000.0 recorded in Q3 2022.
  • In the past 5 years, Protagonist Therapeutics' Exchange Rate Effect ranged from a high of $123000.0 in Q3 2020 and a low of -$175000.0 during Q3 2022
  • Over the past 5 years, Protagonist Therapeutics' median Exchange Rate Effect value was -$14000.0 (recorded in 2019), while the average stood at -$14666.7.
  • Examining YoY changes over the last 5 years, Protagonist Therapeutics' Exchange Rate Effect showed a top increase of 124444.44% in 2020 and a maximum decrease of 100000.0% in 2020.
  • Quarter analysis of 5 years shows Protagonist Therapeutics' Exchange Rate Effect stood at -$87000.0 in 2018, then plummeted by 43.68% to -$125000.0 in 2019, then soared by 116.8% to $21000.0 in 2020, then rose by 4.76% to $22000.0 in 2021, then soared by 240.91% to $75000.0 in 2022.
  • Its Exchange Rate Effect was $75000.0 in Q4 2022, compared to -$175000.0 in Q3 2022 and -$19000.0 in Q2 2022.